SMARCA4 and small cell lung carcinoma: Furthermore, in line with the specific enrichment of SMARCA4 mutations in SCLC-Y tumors, SMARCA4-mutant SCLC cell lines exhibited significantly lower expression of a previously defined neuroendocrine (NE) transcriptomic signature (16, 23) compared with SMARCA4 wildtype SCLC cell lines (Fig. 1D; Supplementary Table S6).